SCHEMBL10135115

SCHEMBL10135115

N#Cc1ccc2c(c1)nc(Oc1ccc(F)cc1)c1ccsc12

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 9/20 0.42
CYP1A2 P05177 3/20 0.40
CYP2C19 P33261 3/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 2/20 0.38
HPGD P15428 4/20 0.38
KDM4E B2RXH2 4/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 2/20 0.38
CSNK2A2 P19784 1/20 0.36
CSNK2B P67870 1/20 0.36
PTGS1 P23219 1/20 0.35
SCN9A Q15858 1/20 0.35
MAPT P10636 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
TDP2 O95551 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10135110 0.89 CSNK2A1 (0.39) CSNK2A1CSNK2A2CSNK2BSMN1; SMN2
SCHEMBL2689569 0.88 CSNK2A1 (0.44) CSNK2A1CYP1A2CYP2C19CYP3A4CYP2C9
SCHEMBL10135114 0.84 RAB9A (0.47) CSNK2A1CYP1A2CYP2C19CYP2C9HPGD
SCHEMBL13688076 0.82 CSNK2A1 (0.43) CSNK2A1CYP1A2CYP2C19CYP2C9KDM4E
SCHEMBL10135116 0.81 CYP19A1 (0.43) CSNK2A1CYP1A2CYP2C19CYP3A4CYP2C9
SCHEMBL10135113 0.81 CSNK2A1 (0.38) CSNK2A1MEN1KMT2AALDH1A1CSNK2A2
SCHEMBL10135095 0.77 CSNK2A1 (0.43) CSNK2A1CSNK2A2CSNK2B
SCHEMBL10135122 0.74 CSNK2A1 (0.45) CSNK2A1
SCHEMBL10135098 0.74 CSNK2A1 (0.45) CSNK2A1KDM4ECSNK2A2CSNK2B
SCHEMBL11932491 0.73 CSNK2A1 (0.45) CSNK2A1CSNK2BSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CSNK2A1 680/4885CYP1A2 4109/4885CYP2C19 3991/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CSNK2A1 680/4885CYP1A2 4109/4885CYP2C19 3991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.